Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2021-10-19 00:00:00 ET · period of report 2021-10-15 · accession 0001209191-21-060957 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-10-19 | 2021-10-15 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +5,938 | 55.9K | +12% | — |
| D | 2021-10-19 | 2021-10-18 | ACAD | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $17.41 | -2,963 | 52.9K | -5% | -$51.6K |
| D | 2021-10-19 | 2021-10-15 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | $0.00 | -5,938 | 5,938 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-15 | M | A | 5,938 | — | 55,869 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 619 shares of the Issuer's common stock acquired by the reporting person on May 14, 2021 pursuant to an employee stock purchase program. |
| 2 | Common | Common Stock | 2021-10-18 | S | D | 2,963 | $17.41 | 52,906 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2021-10-15 | M | D | 5,938 | $0.00 | 5,938 | D | — · — to — | 5,938 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F4) The restricted stock units vest in four equal annual installments beginning 10/15/19. |